Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 152

1.

Recombination of host cell mRNA with the Asia 1 foot-and-mouth disease virus genome in cell suspension culture.

Zou X, Zhu Y, Bao H, Guo X, Sun P, Liu Z, Mason PW, Xu L, Li C, Zhang Q, Wang Q, Zhu H, Zhao Q.

Arch Virol. 2018 Sep 19. doi: 10.1007/s00705-018-4008-2. [Epub ahead of print]

PMID:
30232612
2.

Induction of Broad-Based Immunity and Protective Efficacy by Self-amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin.

Brazzoli M, Magini D, Bonci A, Buccato S, Giovani C, Kratzer R, Zurli V, Mangiavacchi S, Casini D, Brito LM, De Gregorio E, Mason PW, Ulmer JB, Geall AJ, Bertholet S.

J Virol. 2015 Oct 14;90(1):332-44. doi: 10.1128/JVI.01786-15. Print 2016 Jan 1.

3.

Control of alphavirus-based gene expression using engineered riboswitches.

Bell CL, Yu D, Smolke CD, Geall AJ, Beard CW, Mason PW.

Virology. 2015 Sep;483:302-11. doi: 10.1016/j.virol.2015.04.023. Epub 2015 May 23.

4.

Self-amplifying mRNA vaccines.

Brito LA, Kommareddy S, Maione D, Uematsu Y, Giovani C, Berlanda Scorza F, Otten GR, Yu D, Mandl CW, Mason PW, Dormitzer PR, Ulmer JB, Geall AJ.

Adv Genet. 2015;89:179-233. doi: 10.1016/bs.adgen.2014.10.005. Epub 2014 Dec 4.

PMID:
25620012
5.

A cationic nanoemulsion for the delivery of next-generation RNA vaccines.

Brito LA, Chan M, Shaw CA, Hekele A, Carsillo T, Schaefer M, Archer J, Seubert A, Otten GR, Beard CW, Dey AK, Lilja A, Valiante NM, Mason PW, Mandl CW, Barnett SW, Dormitzer PR, Ulmer JB, Singh M, O'Hagan DT, Geall AJ.

Mol Ther. 2014 Dec;22(12):2118-29. doi: 10.1038/mt.2014.133. Epub 2014 Jul 16.

6.

Human cytomegalovirus gH/gL/UL128/UL130/UL131A complex elicits potently neutralizing antibodies in mice.

Wen Y, Monroe J, Linton C, Archer J, Beard CW, Barnett SW, Palladino G, Mason PW, Carfi A, Lilja AE.

Vaccine. 2014 Jun 24;32(30):3796-804. doi: 10.1016/j.vaccine.2014.05.004. Epub 2014 May 14.

PMID:
24837507
7.

Subcapsular sinus macrophages limit dissemination of West Nile virus particles after inoculation but are not essential for the development of West Nile virus-specific T cell responses.

Winkelmann ER, Widman DG, Xia J, Johnson AJ, van Rooijen N, Mason PW, Bourne N, Milligan GN.

Virology. 2014 Feb;450-451:278-89. doi: 10.1016/j.virol.2013.12.021. Epub 2014 Jan 10.

8.

Engineered alphavirus replicon vaccines based on known attenuated viral mutants show limited effects on immunogenicity.

Maruggi G, Shaw CA, Otten GR, Mason PW, Beard CW.

Virology. 2013 Dec;447(1-2):254-64. doi: 10.1016/j.virol.2013.07.021. Epub 2013 Oct 5.

9.
10.

Improving influenza virus backbones by including terminal regions of MDCK-adapted strains on hemagglutinin and neuraminidase gene segments.

Gomila RC, Suphaphiphat P, Judge C, Spencer T, Ferrari A, Wen Y, Palladino G, Dormitzer PR, Mason PW.

Vaccine. 2013 Oct 1;31(42):4736-43. doi: 10.1016/j.vaccine.2013.08.026. Epub 2013 Aug 20.

PMID:
23973324
11.

Rapidly produced SAM(®) vaccine against H7N9 influenza is immunogenic in mice.

Hekele A, Bertholet S, Archer J, Gibson DG, Palladino G, Brito LA, Otten GR, Brazzoli M, Buccato S, Bonci A, Casini D, Maione D, Qi ZQ, Gill JE, Caiazza NC, Urano J, Hubby B, Gao GF, Shu Y, De Gregorio E, Mandl CW, Mason PW, Settembre EC, Ulmer JB, Craig Venter J, Dormitzer PR, Rappuoli R, Geall AJ.

Emerg Microbes Infect. 2013 Aug;2(8):e52. doi: 10.1038/emi.2013.54. Epub 2013 Aug 14.

12.

Generation of a parvovirus B19 vaccine candidate.

Chandramouli S, Medina-Selby A, Coit D, Schaefer M, Spencer T, Brito LA, Zhang P, Otten G, Mandl CW, Mason PW, Dormitzer PR, Settembre EC.

Vaccine. 2013 Aug 20;31(37):3872-8. doi: 10.1016/j.vaccine.2013.06.062. Epub 2013 Jul 2.

PMID:
23827313
13.

Synthetic generation of influenza vaccine viruses for rapid response to pandemics.

Dormitzer PR, Suphaphiphat P, Gibson DG, Wentworth DE, Stockwell TB, Algire MA, Alperovich N, Barro M, Brown DM, Craig S, Dattilo BM, Denisova EA, De Souza I, Eickmann M, Dugan VG, Ferrari A, Gomila RC, Han L, Judge C, Mane S, Matrosovich M, Merryman C, Palladino G, Palmer GA, Spencer T, Strecker T, Trusheim H, Uhlendorff J, Wen Y, Yee AC, Zaveri J, Zhou B, Becker S, Donabedian A, Mason PW, Glass JI, Rappuoli R, Venter JC.

Sci Transl Med. 2013 May 15;5(185):185ra68. doi: 10.1126/scitranslmed.3006368.

14.

Vectored co-delivery of human cytomegalovirus gH and gL proteins elicits potent complement-independent neutralizing antibodies.

Loomis RJ, Lilja AE, Monroe J, Balabanis KA, Brito LA, Palladino G, Franti M, Mandl CW, Barnett SW, Mason PW.

Vaccine. 2013 Jan 30;31(6):919-26. doi: 10.1016/j.vaccine.2012.12.009. Epub 2012 Dec 14.

PMID:
23246547
15.

The next generation recombinant human cytomegalovirus vaccine candidates-beyond gB.

Lilja AE, Mason PW.

Vaccine. 2012 Nov 19;30(49):6980-90. doi: 10.1016/j.vaccine.2012.09.056. Epub 2012 Oct 3. Review.

PMID:
23041121
16.

Adoption as an intervention for institutionally reared children: HPA functioning and developmental status.

Kroupina MG, Fuglestad AJ, Iverson SL, Himes JH, Mason PW, Gunnar MR, Miller BS, Petryk A, Johnson DE.

Infant Behav Dev. 2012 Dec;35(4):829-37. doi: 10.1016/j.infbeh.2012.07.011. Epub 2012 Sep 14.

PMID:
22986178
17.

Nonviral delivery of self-amplifying RNA vaccines.

Geall AJ, Verma A, Otten GR, Shaw CA, Hekele A, Banerjee K, Cu Y, Beard CW, Brito LA, Krucker T, O'Hagan DT, Singh M, Mason PW, Valiante NM, Dormitzer PR, Barnett SW, Rappuoli R, Ulmer JB, Mandl CW.

Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14604-9. doi: 10.1073/pnas.1209367109. Epub 2012 Aug 20.

18.

RNA-based vaccines.

Ulmer JB, Mason PW, Geall A, Mandl CW.

Vaccine. 2012 Jun 22;30(30):4414-8. doi: 10.1016/j.vaccine.2012.04.060. Epub 2012 Apr 28. Review.

PMID:
22546329
19.

Synergistic interactions between the NS3(hel) and E proteins contribute to the virulence of dengue virus type 1.

de Borba L, Strottmann DM, de Noronha L, Mason PW, Dos Santos CN.

PLoS Negl Trop Dis. 2012;6(4):e1624. doi: 10.1371/journal.pntd.0001624. Epub 2012 Apr 17.

20.

Intrinsic adjuvanting of a novel single-cycle flavivirus vaccine in the absence of type I interferon receptor signaling.

Winkelmann ER, Widman DG, Xia J, Ishikawa T, Miller-Kittrell M, Nelson MH, Bourne N, Scholle F, Mason PW, Milligan GN.

Vaccine. 2012 Feb 14;30(8):1465-75. doi: 10.1016/j.vaccine.2011.12.103. Epub 2012 Jan 5.

21.
22.

Enhancing the utility of a prM/E-expressing chimeric vaccine for Japanese encephalitis by addition of the JEV NS1 gene.

Ishikawa T, Wang G, Widman DG, Infante E, Winkelmann ER, Bourne N, Mason PW.

Vaccine. 2011 Oct 6;29(43):7444-55. doi: 10.1016/j.vaccine.2011.07.058. Epub 2011 Jul 26.

PMID:
21798299
23.

Repeated in vivo stimulation of T and B cell responses in old mice generates protective immunity against lethal West Nile virus encephalitis.

Uhrlaub JL, Brien JD, Widman DG, Mason PW, Nikolich-Zugich J.

J Immunol. 2011 Apr 1;186(7):3882-91. doi: 10.4049/jimmunol.1002799. Epub 2011 Feb 21.

24.

Immunogenicity of RepliVAX WN, a novel single-cycle West Nile virus vaccine.

Nelson MH, Winkelmann E, Ma Y, Xia J, Mason PW, Bourne N, Milligan GN.

Vaccine. 2010 Dec 16;29(2):174-82. doi: 10.1016/j.vaccine.2010.10.069. Epub 2010 Nov 4.

25.

Mutations at positions 186 and 194 in the HA gene of the 2009 H1N1 pandemic influenza virus improve replication in cell culture and eggs.

Suphaphiphat P, Franti M, Hekele A, Lilja A, Spencer T, Settembre E, Palmer G, Crotta S, Tuccino AB, Keiner B, Trusheim H, Balabanis K, Sackal M, Rothfeder M, Mandl CW, Dormitzer PR, Mason PW.

Virol J. 2010 Jul 14;7:157. doi: 10.1186/1743-422X-7-157.

26.

Simultaneous detection of avian influenza virus NP and H5 antibodies in chicken sera using a fluorescence microsphere immunoassay.

Lupiani B, Mozisek B, Mason PW, Lamichhane C, Reddy SM.

Avian Dis. 2010 Mar;54(1 Suppl):668-72.

PMID:
20521712
27.

Evaluation of RepliVAX WN, a single-cycle flavivirus vaccine, in a non-human primate model of West Nile virus infection.

Widman DG, Ishikawa T, Giavedoni LD, Hodara VL, Garza Mde L, Montalbo JA, Travassos Da Rosa AP, Tesh RB, Patterson JL, Carrion R Jr, Bourne N, Mason PW.

Am J Trop Med Hyg. 2010 Jun;82(6):1160-7. doi: 10.4269/ajtmh.2010.09-0310.

28.

Conjugation to nickel-chelating nanolipoprotein particles increases the potency and efficacy of subunit vaccines to prevent West Nile encephalitis.

Fischer NO, Infante E, Ishikawa T, Blanchette CD, Bourne N, Hoeprich PD, Mason PW.

Bioconjug Chem. 2010 Jun 16;21(6):1018-22. doi: 10.1021/bc100083d.

29.
30.

The NS5 protein of the virulent West Nile virus NY99 strain is a potent antagonist of type I interferon-mediated JAK-STAT signaling.

Laurent-Rolle M, Boer EF, Lubick KJ, Wolfinbarger JB, Carmody AB, Rockx B, Liu W, Ashour J, Shupert WL, Holbrook MR, Barrett AD, Mason PW, Bloom ME, García-Sastre A, Khromykh AA, Best SM.

J Virol. 2010 Apr;84(7):3503-15. doi: 10.1128/JVI.01161-09. Epub 2010 Jan 27.

31.

Human RNA polymerase I-driven reverse genetics for influenza a virus in canine cells.

Suphaphiphat P, Keiner B, Trusheim H, Crotta S, Tuccino AB, Zhang P, Dormitzer PR, Mason PW, Franti M.

J Virol. 2010 Apr;84(7):3721-5. doi: 10.1128/JVI.01925-09. Epub 2010 Jan 13.

32.

Construction and characterization of a stable subgenomic replicon system of a Brazilian dengue virus type 3 strain (BR DEN3 290-02).

Mosimann AL, de Borba L, Bordignon J, Mason PW, dos Santos CN.

J Virol Methods. 2010 Jan;163(1):147-52. doi: 10.1016/j.jviromet.2009.09.004. Epub 2009 Sep 15.

PMID:
19761796
33.

RepliVAX WN, a single-cycle flavivirus vaccine to prevent West Nile disease, elicits durable protective immunity in hamsters.

Widman DG, Ishikawa T, Winkelmann ER, Infante E, Bourne N, Mason PW.

Vaccine. 2009 Sep 18;27(41):5550-3. doi: 10.1016/j.vaccine.2009.07.016. Epub 2009 Jul 25.

PMID:
19635608
34.

Infection, dissemination, and transmission of a West Nile virus green fluorescent protein infectious clone by Culex pipiens quinquefasciatus mosquitoes.

McGee CE, Shustov AV, Tsetsarkin K, Frolov IV, Mason PW, Vanlandingham DL, Higgs S.

Vector Borne Zoonotic Dis. 2010 Apr;10(3):267-74. doi: 10.1089/vbz.2009.0067.

35.

Antiviral activity of geneticin against dengue virus.

Zhang XG, Mason PW, Dubovi EJ, Xu X, Bourne N, Renshaw RW, Block TM, Birk AV.

Antiviral Res. 2009 Jul;83(1):21-7. doi: 10.1016/j.antiviral.2009.02.204. Epub 2009 Mar 11.

36.

West nile virus capsid degradation of claudin proteins disrupts epithelial barrier function.

Medigeshi GR, Hirsch AJ, Brien JD, Uhrlaub JL, Mason PW, Wiley C, Nikolich-Zugich J, Nelson JA.

J Virol. 2009 Jun;83(12):6125-34. doi: 10.1128/JVI.02617-08. Epub 2009 Apr 15.

37.

Immobilization of His-tagged proteins on nickel-chelating nanolipoprotein particles.

Fischer NO, Blanchette CD, Chromy BA, Kuhn EA, Segelke BW, Corzett M, Bench G, Mason PW, Hoeprich PD.

Bioconjug Chem. 2009 Mar 18;20(3):460-5. doi: 10.1021/bc8003155.

PMID:
19239247
38.

West Nile virus genome amplification requires the functional activities of the proteasome.

Gilfoy F, Fayzulin R, Mason PW.

Virology. 2009 Mar 1;385(1):74-84. doi: 10.1016/j.virol.2008.11.034. Epub 2008 Dec 19.

39.

Third-generation flavivirus vaccines based on single-cycle, encapsidation-defective viruses.

Widman DG, Frolov I, Mason PW.

Adv Virus Res. 2008;72:77-126. doi: 10.1016/S0065-3527(08)00402-8. Review.

PMID:
19081489
40.
41.

RNA interference screen for human genes associated with West Nile virus infection.

Krishnan MN, Ng A, Sukumaran B, Gilfoy FD, Uchil PD, Sultana H, Brass AL, Adametz R, Tsui M, Qian F, Montgomery RR, Lev S, Mason PW, Koski RA, Elledge SJ, Xavier RJ, Agaisse H, Fikrig E.

Nature. 2008 Sep 11;455(7210):242-5. doi: 10.1038/nature07207.

42.

Identification of mutated cyclization sequences that permit efficient replication of West Nile virus genomes: use in safer propagation of a novel vaccine candidate.

Suzuki R, Fayzulin R, Frolov I, Mason PW.

J Virol. 2008 Jul;82(14):6942-51. doi: 10.1128/JVI.00662-08. Epub 2008 May 14.

43.

Construction and evaluation of a chimeric pseudoinfectious virus vaccine to prevent Japanese encephalitis.

Ishikawa T, Widman DG, Bourne N, Konishi E, Mason PW.

Vaccine. 2008 May 23;26(22):2772-81. doi: 10.1016/j.vaccine.2008.03.010. Epub 2008 Mar 31.

PMID:
18433947
44.

Construction and characterization of a second-generation pseudoinfectious West Nile virus vaccine propagated using a new cultivation system.

Widman DG, Ishikawa T, Fayzulin R, Bourne N, Mason PW.

Vaccine. 2008 May 23;26(22):2762-71. doi: 10.1016/j.vaccine.2008.03.009. Epub 2008 Mar 31.

PMID:
18423946
45.

Differential activation of human monocyte-derived and plasmacytoid dendritic cells by West Nile virus generated in different host cells.

Silva MC, Guerrero-Plata A, Gilfoy FD, Garofalo RP, Mason PW.

J Virol. 2007 Dec;81(24):13640-8. Epub 2007 Oct 3.

46.

Production of pseudoinfectious yellow fever virus with a two-component genome.

Shustov AV, Mason PW, Frolov I.

J Virol. 2007 Nov;81(21):11737-48. Epub 2007 Aug 22.

47.

Non-specific antiviral response detected in RNA-treated cultured cells of the sandfly, Lutzomyia longipalpis.

Pitaluga AN, Mason PW, Traub-Cseko YM.

Dev Comp Immunol. 2008;32(3):191-7. Epub 2007 Jul 23.

PMID:
17706772
48.

West Nile virus infection activates the unfolded protein response, leading to CHOP induction and apoptosis.

Medigeshi GR, Lancaster AM, Hirsch AJ, Briese T, Lipkin WI, Defilippis V, Früh K, Mason PW, Nikolich-Zugich J, Nelson JA.

J Virol. 2007 Oct;81(20):10849-60. Epub 2007 Aug 8.

49.
50.

Early production of type I interferon during West Nile virus infection: role for lymphoid tissues in IRF3-independent interferon production.

Bourne N, Scholle F, Silva MC, Rossi SL, Dewsbury N, Judy B, De Aguiar JB, Leon MA, Estes DM, Fayzulin R, Mason PW.

J Virol. 2007 Sep;81(17):9100-8. Epub 2007 Jun 13.

Supplemental Content

Loading ...
Support Center